Retatrutide Explained: How It Works, Trials and FDA Status

Retatrutide is not approved by the FDA and has not been proven safe or effective for any treatment. This article is for educational purposes only and does not recommend or encourage the use of this substance. NiceRx does not offer or prescribe retatrutide.

Retatrutide, often shortened to "reta," is a medicine Eli Lilly is still testing. It keeps showing up in the news and in search results, so here is a plain rundown of what it is, where it stands with the FDA, and what researchers are studying. It won't tell you how to use it. There's no approved way to.

What is retatrutide?

Retatrutide is an investigational once-weekly injection from Eli Lilly. Lilly calls it a triple hormone receptor agonist: one molecule built to switch on three receptors, for GIP, GLP-1 and glucagon. In trial registries it goes by the development code LY3437943.

"Investigational" has a specific meaning. The FDA hasn't approved retatrutide for anything, and Lilly says it can't legally be sold or marketed for human use.

How it's designed to work

GIP, GLP-1 and glucagon are natural hormones, and each acts through its own receptor. Retatrutide is built to act on all three receptors at once.

That's the design difference researchers point to. The Wegovy label describes semaglutide as a GLP-1 receptor agonist, and the Zepbound label describes tirzepatide as a GIP and GLP-1 receptor agonist. Whether a third target changes anything for real patients is what the trials are there to find out, so this page doesn't guess.

Where retatrutide stands with the FDA

It isn't approved. A few facts sit behind that.

• Lilly describes retatrutide as an investigational molecule that cannot be legally sold or marketed for human use.

• The FDA says retatrutide can't be used in compounding, isn't part of any approved drug, and hasn't been found safe and effective for any condition.

• In July 2026 Lilly said it now has the clinical data package to support submissions to regulators. A submission isn't an approval. Nobody outside the FDA can say when, or whether, one will come.

A short history

Lilly's Phase 3 trials began in 2023, according to the trial registry. Since then the company has announced topline results from TRIUMPH-4 (December 11, 2025), TRANSCEND-T2D-1 (March 19, 2026), and TRIUMPH-2 and TRIUMPH-3 (July 23, 2026). The New England Journal of Medicine published the TRIUMPH-1 trial on September 29, 2026.

We're not summarizing findings here. They belong to the trial teams and the journals, and the sources below link straight to them.

What researchers are studying

The conditions named in Lilly's announcements are obesity and overweight, type 2 diabetes, knee osteoarthritis pain, sleep apnea, chronic low back pain, heart and kidney outcomes, and fatty liver disease. This is how the four Phase 3 TRIUMPH trials are set up, from the public registry:

All four are randomized, double-blind and placebo-controlled.

How retatrutide differs from semaglutide and tirzepatide

This compares design and approval status. It says nothing about how well any of them works or how safe they are.

Questions people ask

Is retatrutide FDA-approved?

No. It's an investigational medicine from Eli Lilly, still in Phase 3 testing.

Can you buy retatrutide legally?

Lilly says it can't be legally sold or marketed for human use, and the FDA says it can't be used in compounding. Products sold online under the name aren't FDA-approved medicines.

When will retatrutide be approved?

Nobody can say. Approval depends on the FDA reviewing the trial data, and Lilly hasn't announced a date. We'll update this page if that changes.

Can you switch from semaglutide or tirzepatide to retatrutide?

There's no approved way to. Retatrutide has no FDA label and no switching guidance, and it isn't legally available outside Lilly's trials. If you're thinking about changing medicines, a licensed clinician is the person to ask about approved options.

Is there an FDA-approved alternative?

Nothing replaces it one for one, because it isn't approved. The FDA has approved other medicines for chronic weight management, including Wegovy (semaglutide) and Zepbound (tirzepatide), as their prescribing information shows. Whether either suits you is a question for a clinician.

How much does retatrutide cost?

It has no price, because it isn't approved or legally for sale. Be careful with anyone who quotes you one.

More on retatrutide

• Retatrutide dosage chart: clinical trial doses (not approved)

• Retatrutide starting dose: trial doses (not approved)

• Retatrutide (reta) side effects: what trials reported

Retatrutide is not approved by the FDA and has not been proven safe or effective for any treatment. This article is for educational purposes only and does not recommend or encourage the use of this substance. NiceRx does not offer or prescribe retatrutide.